값202020212022202320242025TTM판매비·일반관리비———————연구개발———————영업 이익———————비영업 수익, 합계———————이자비용(자본화한 이자 차감 후)———————이자비용을 제외한 비영업 수익———————비정상 수입/지출———————세전소득———————지분법 손익———————세금———————비지배 지분———————세후 기타 수익/비용———————중단된 사업 부문 제외 순이익———————중단된 사업———————순이익———————희석보정———————우선배당———————보통주주에게 귀속되는 희석 순이익———————주당 순이익(기본 EPS)———————희석 주당 순이익 (희석 EPS)———————평균 발행주식수———————희석주식수———————EBITDA———————EBIT———————매출원가———————기타 매출원가———————감가상각 및 무형자산 상각 (현금흐름)———————
GSK plc American Depositary Shares (Each representing two Ordin
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost.